A newly developed oral carbacephem, loracarbef (LCBF), was evaluated in vitro and in vivo in comparison with cefaclor (CCL), cefixime, cefotiam and amoxicillin. The results were as follows. 1. Antimicrobial activity: Minimal inhibitory concentrations (MICs) against 419 clinical isolates including 12 different species were determined by the microbroth dilution method. LCBF showed good antimicrobial activity against gram-positive and -negative bacteria except methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa and Acinetobacter anitratus. The MICs of LCBF were almost the same as those of the first-generation oral cephem, CCL. 2. LCBF concentration in plasma and sputum: Two patients with diffuse panbronchiolitis were given 200 mg or 400 mg of LCBF orally, and its concentrations in plasma and sputum were measured at intervals using HPLC. The peak concentrations of LCBF in the serum and sputum of a patient administered 200 mg were 8.34 and 0.47 μg/ml, respectively, and those of a patient administered 400 mg were 16.1 and 0.36 μg/ml, respectively. From these data, it was suggested that LCBF had good penetration into the blood and lung. 3. Clinical efficacy and adverse reaction: Twenty-one patients with respiratory tract infections were treated with LCBF, and the overall efficacy rate was 65% (good in 13, fair in 3, poor in 4, not evaluable in 1). Stomach discomfort was observed as a side effect.
|出版ステータス||Published - 1993 1 1|
ASJC Scopus subject areas